{"DataElement":{"publicId":"2752647","version":"1","preferredName":"Chemotherapy Procarbazine java.lang.Boolean","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction._Generic value domain for a primitive java datatype that is a Boolean value (true or false).","longName":"2752131v1.0:2178538v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2752131","version":"1","preferredName":"Chemotherapy Procarbazine","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)_A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","longName":"2404910v1.0:2751793v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2404910","version":"1","preferredName":"Chemotherapy","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"C15632","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0094ACAF-12DD-1BCA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-09-13","modifiedBy":"ONEDATA","dateModified":"2005-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2751793","version":"1","preferredName":"Procarbazine","preferredDefinition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","longName":"C62072","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DDDB0A1-A4FF-530B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-22","endDate":null,"createdBy":"UMLLOADER_LEADS","dateCreated":"2008-05-22","modifiedBy":"ONEDATA","dateModified":"2008-05-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DDF3B0A-97AC-477C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-22","endDate":null,"createdBy":"UMLLOADER_LEADS","dateCreated":"2008-05-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"1/1/11 Released as part of Lymphoma Enterprise Architecture Data System (LEADS) model cleanup.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2178538","version":"1","preferredName":"java.lang.Boolean","preferredDefinition":"Generic value domain for a primitive java datatype that is a Boolean value (true or false).","longName":"java.lang.Boolean","context":"caCORE","contextVersion":"1","type":"Non-enumerated","dataType":"java.lang.Boolean","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2178532","version":"1","preferredName":"Bioinformatics","preferredDefinition":".","longName":"BIOINFORMATICS","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"CD81DD3C-8FFA-28BA-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-02","endDate":"2020-10-14","createdBy":"SBREXT","dateCreated":"2003-12-02","modifiedBy":"TAYLORT","dateModified":"2020-10-14","changeDescription":"10.14.20 TL changed WFS from DRAFT NEW to RETIRED ARCHIVED and added an End Date in preparation of OneData.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD831153-DAB5-28B6-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-02","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-02","modifiedBy":"CURTIST","dateModified":"2007-12-05","changeDescription":"03/30/2006 - Updated defintion and datatype (previously Boolean).","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2751669","version":"1","longName":"Lymphoma Enterprise Architecture Data System (LEADS)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2813014","version":"1","longName":"edu.emory.wci.lymphoma","context":"NCIP"}]}],"AlternateNames":[{"name":"edu.emory.wci.lymphoma.Chemotherapy.procarbazine","type":"UML Qualified Attr","context":"NCIP"},{"name":"Chemotherapy:procarbazine","type":"UML Class:UML Attr","context":"NCIP"}],"ReferenceDocuments":[{"name":"Data Element Chemotherapy Procarbazine java.lang.Boolean does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Chemotherapy Procarbazine java.lang.Boolean does not have Preferred Question Text","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4DDEB907-1D85-2DBB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-22","endDate":null,"createdBy":"UMLLOADER_LEADS","dateCreated":"2008-05-23","modifiedBy":"CHILLIJ","dateModified":"2011-01-02","changeDescription":"1/1/11 Released as part of Lymphoma Enterprise Architecture Data System (LEADS) model cleanup","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}